在肉瘤患者中对治疗决策的偏好:流行率和相关因素 - - PROSa研究的结果
Hanna Salm1,2, Markus K Schuler3, Leopold Hentschel4
1Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany.
Oncology research and treatment
|January 15, 2025
概括
瘤患者的患者.
科学领域:
- 在瘤学瘤学.
- 医学社会学 医学社会学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 危及生命的诊断可以改变患者对治疗决策的偏好.
- 了解这些偏好对于瘤学中以患者为中心的护理至关重要.
研究的目的:
- 确定与肉瘤患者在治疗决策中积极或被动地发挥作用的愿望相关的因素.
- 为医疗保健提供者提供量身定制的沟通策略.
主要方法:
- 在德国全国多中心研究 (PROSa) 中,对1081名成年肉瘤患者的横截面数据进行分析.
- 使用控制偏好尺度 (CPS) 测量控制偏好,分为患者主导,共享或医生主导的决策.
- 使用多变量多项物流回归的探索性分析,以确定相关的社会经济和医疗因素.
主要成果:
- 37.2%的患者更喜欢主动控制,37.0%更喜欢共享决策,25.8%更喜欢由医生领导的决策.
- 老年患者 (>75岁) 与年轻患者 (18-40岁) 相比,不太可能喜欢主动或共享决策.
- 患有转移性疾病和较高收入水平的患者更倾向于主动或共享决策.
- 高等教育水平与偏好患者主导的决策而不是医生主导的决策相关.
结论:
- 患者对瘤治疗决策的偏好因年龄,教育,疾病状态 (转移) 和社会经济因素而异.
- 转移性疾病和更高的社会经济地位与更大的参与治疗决策的愿望有关.
- 年龄较大和教育程度较低与偏好在治疗决策中扮演更被动的角色有关,这表明晚期疾病会影响参与.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...